B cell homeostasis and the development of chronic graft-versus-host disease: Implications for B cell-depleting therapy

Leukemia and Lymphoma

Volumn 53, Issue 1, 2012, Pages 19-25

  Kim, Seok Jin ^a   Won, Jong Ho ^b  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Soonchunhyang University College of Medicine   (South Korea)

Author keywords

Allogeneic stem cell transplant; B cell homeostasis; Chronic GVHD; Rituximab

Indexed keywords

B CELL ACTIVATING FACTOR; B LYMPHOCYTE RECEPTOR; RITUXIMAB;

ALLOGENEIC STEM CELL TRANSPLANTATION; B LYMPHOCYTE; CELL DIFFERENTIATION; CHRONIC GRAFT VERSUS HOST DISEASE; DISEASE COURSE; DRUG EFFICACY; HOMEOSTASIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; CHRONIC DISEASE; GRAFT VS HOST DISEASE; HOMEOSTASIS; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOCYTE DEPLETION; MODELS, IMMUNOLOGICAL; STEM CELL TRANSPLANTATION;

EID: 84855435165     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.603448     Document Type: Review

References (54)

1. Ayash L, Lazarus HM, et al. Chronic graftversus- host disease: clinical manifestation and therapy. Bone Marrow Transplant 2001;28:121-129. (Pubitemid 32725712)
2. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006;354:1813-1826.
3. Karanes C, Nelson GO, Chitphakdithai P, et al. Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program. Biol Blood Marrow Transplant 2008;14:8-15.
4. Arora M, Wagner JE, Davies SM, et al. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant 2001;7:265-273. (Pubitemid 32591297)
5. Koc S, Leisenring W, Flowers ME, et al. Th erapy for chronic graftversus- host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood 2002;100:48-51. (Pubitemid 35177427)
6. G oulmy E, Schipper R, Pool J, et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996;334:281-285. (Pubitemid 26033083)
7. Biedermann BC, Sahner S, Gregor M, et al. Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet 2002;359:2078-2083. (Pubitemid 34680972)
8. Socie G, Ritz J, Martin PJ. Current challenges in chronic graft-versushost disease. Biol Blood Marrow Transplant 2010;16:S146-S151.
9. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003;9:215-233. (Pubitemid 40045609)
10. Patriarca F, Skert C, Sperotto A, et al. Th e development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery. Exp Hematol 2006;34:389-396.
11. Svegliati S, Olivieri A, Campelli N, et al. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood 2007;110:237-241. (Pubitemid 47026840)
12. Z hang C, Todorov I, Zhang Z, et al. Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. Blood 2006;107:2993-3001.
13. M iklos DB, Kim HT, Miller KH, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versushost disease and disease remission. Blood 2005;105:2973-2978. (Pubitemid 40446295)
14. M iklos DB, Kim HT, Zorn E, et al. Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood 2004;103:353-359. (Pubitemid 38035116)
15. R atanatharathorn V, Carson E, Reynolds C, et al. Anti-CD20 chimeric monoclonal antibody treatment of refractory immunemediated thrombocytopenia in a patient with chronic graft-versushost disease. Ann Intern Med 2000;133:275-279. (Pubitemid 30660299)
16. R atanatharathorn V, Ayash L, Reynolds C, et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 2003;9:505-511. (Pubitemid 38351794)
17. O kamoto M, Okano A, Akamatsu S, et al. Rituximab is eff ective for steroid-refractory sclerodermatous chronic graft-versus-host disease. Leukemia 2006;20:172-173.
18. M ohty M, Marchetti N, El-Cheikh J, et al. Rituximab as salvage therapy for refractory chronic GVHD. Bone Marrow Transplant 2008;41:909-911. (Pubitemid 351761695)
19. Z aja F, Bacigalupo A, Patriarca F, et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant 2007;40:273-277. (Pubitemid 47108472)
20. C anninga-van Dijk MR, van der Straaten HM, Fijnheer R, et al. Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Blood 2004;104: 2603-2606. (Pubitemid 39331867)
21. C utler C, Miklos D, Kim HT, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006;108:756-762. (Pubitemid 44061381)
22. T eshima T, Nagafuji K, Henzan H, et al. Rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease. Int J Hematol 2009;90:253-260.
23. K harfan-Dabaja MA, Mhaskar AR, Djulbegovic B, et al. Effi cacy of ituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. Biol Blood Marrow Transplant 2009;15:1005-1013.
24. K im SJ, Lee JW, Jung CW, et al. Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graftversus- host disease: results from a prospective, multicenter, phase II study. Haematologica 2010;95:1935-1942.
25. S arantopoulos S, Stevenson KE, Kim HT, et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood 2009;113:3865-3874.
26. S arantopoulos S, Stevenson KE, Kim HT, et al. Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. Blood 2011;117:2275-2283.
27. K han WN. B cell receptor and BAFF receptor signaling regulation of B cell homeostasis. J Immunol 2009;183:3561-3567.
28. C ancro MP. Signalling crosstalk in B cells: managing worth and need. Nat Rev Immunol 2009;9:657-661.
29. W ardemann H, Yurasov S, Schaefer A, et al. Predominant autoantibody production by early human B cell precursors. Science 2003;301:1374-1377. (Pubitemid 37075812)
30. N emazee DA, Burki K. Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. Nature 1989;337:562-566. (Pubitemid 19045542)
31. H artley SB, Crosbie J, Brink R, et al. Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membranebound antigens. Nature 1991;353:765-769. (Pubitemid 21912617)
32. A llman DM, Ferguson SE, Lentz VM, et al. Peripheral B cell maturation. II. Heat-stable antigen(hi) splenic B cells are an immature developmental intermediate in the production of long-lived marrowderived B cells. J Immunol 1993;151:4431-4444. (Pubitemid 23318496)
33. Treml JF, Hao Y, Stadanlick JE, et al. Th e BLyS family: toward a molecular understanding of B cell homeostasis. Cell Biochem Biophys 2009;53:1-16.
34. M ackay F, Schneider P, Rennert P, et al. BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol 2003;21:231-264. (Pubitemid 37174532)
35. B atten M, Groom J, Cachero TG, et al. BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med 2000;192:1453-1466.
36. Hsu BL, Harless SM, Lindsley RC, et al. Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J Immunol 2002;168:5993-5996. (Pubitemid 34620011)
37. Lentz VM, Hayes CE, Cancro MP. Bcmd decreases the life span of B-2 but not B-1 cells in A/WySnJ mice. J Immunol 1998;160: 3743-3747. (Pubitemid 28176076)
38. L am KP, Kuhn R, Rajewsky K. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell 1997;90:1073-1083. (Pubitemid 27408521)
39. Kraus M, Alimzhanov MB, Rajewsky N, et al. Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell 2004;117:787-800. (Pubitemid 38748894)
40. L esley R, Xu Y, Kalled SL, et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004;20:441-453. (Pubitemid 38482122)
41. Th ien M, Phan TG, Gardam S, et al. Excess BAFF rescues selfreactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004;20: 785-798. (Pubitemid 38757447)
42. S tadanlick JE, Kaileh M, Karnell FG, et al. Tonic B cell antigen receptor signals supply an NF-kappaB substrate for prosurvival BLyS signaling. Nat Immunol 2008;9:1379-1387.
43. Sen R. Control of B lymphocyte apoptosis by the transcription factor NF-kappaB. Immunity 2006;25:871-883. (Pubitemid 44894957)
44. Woodland RT, Fox CJ, Schmidt MR, et al. Multiple signaling pathways promote B lymphocyte stimulator dependent B-cell growth and survival. Blood 2008;111:750-760.
45. Shimabukuro-Vornhagen A, Hallek MJ, Storb RF, et al. Th e role of B cells in the pathogenesis of graft-versus-host disease. Blood 2009;114:4919-4927.
46. C orre E, Carmagnat M, Busson M, et al. Long-term immune defi ciency after allogeneic stem cell transplantation: B-cell defi ciency is associated with late infections. Haematologica 2010;95:1025-1029.
47. S torek J, Ferrara S, Ku N, et al. B cell reconstitution after human bone marrow transplantation: recapitulation of ontogeny? Bone Marrow Transplant 1993;12:387-398. (Pubitemid 23295523)
48. S torek J, Witherspoon RP, Storb R. Reconstitution of membrane IgD- (mIgD-) B cells after marrow transplantation lags behind the reconstitution of mIgD- B cells. Blood 1997;89:350-351. (Pubitemid 26428216)
49. Sarantopoulos S, Stevenson KE, Kim HT, et al. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res 2007;13:6107-6114. (Pubitemid 350075069)
50. A lousi AM, Uberti J, Ratanatharathorn V. Th e role of B cell depleting therapy in graft versus host disease after allogeneic hematopoietic cell transplant. Leuk Lymphoma 2010;51:376-389.
51. Taylor RP, Lindorfer MA. Drug insight: the mechanism of action of rituximab in autoimmune disease-the immune complex decoy hypothesis. Nat Clin Pract Rheumatol 2007;3:86-95.
52. S tasi R, Cooper N, Del Poeta G, et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 2008;112:1147-1150.
53. Roll P, Palanichamy A, Kneitz C, et al. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 2006;54:2377-2386. (Pubitemid 44204997)
54. von Bonin M, Oelschlagel U, Radke J, et al. Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab. Transplantation 2008;86:875-879.